Examining Health Equity Among Different Racial and Ethnic Subpopulations With Multiple Sclerosis - Episode 10

Practical Steps to Mitigating Health Iniquity

References
1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
doi: 10.1038/s41572-018-0041-4
2. Who gets MS? (Epidemiology). National Multiple Sclerosis Society website. Accessed December 22, 2020. https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS
3. Yalachkov Y, Soydaş D, Bergmann J, et al. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30:33-37. doi: 10.1016/j.msard.2019.01.049
4. Coyle P, Robinson J, Schobel V. Initial multiple sclerosis DMT recommendation: impact of comorbidities and prognostic profile in the United States. Presented at: ECTRIMS 2019. September 11-13, 2019; Stockholm, Sweden. Abstract P1351.
5. Jaworski M, Wijcik C, Youngs M, et al. Employment outcomes in multiple sclerosis. Presented at: MSVirtual2020: 8th ACTRIMS-ECTRIMS Meeting; September 11-13, 2020. Presentation P1026.
6. Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis.
J Neurol. 2016;263(6):1053-1065. doi: 10.1007/s00415-015-7986-y
7. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-647.
doi: 10.3111/13696998.2013.778268
8. Anderson SS, Philbrick AM. Improving multiple sclerosis care: an analysis of the necessity for medication therapy management services among the patient population. J Manag Care Spec Pharm. 2014;20(3):254-261. doi: 10.18553/jmcp.2014.20.3.254
9. Fabius CD, Thomas, KS, Zhang T, Ogarek J, Shireman TI. Racial disparities in Medicaid home and community-based service utilization and expenditures among person with multiple sclerosis. BMC Health Serv Res. 2018;18(1):773. doi: 10.1186/s12913-018-3584-x
10. Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations. Neurology: Clinical Practice. 2015;5(2):132-142. doi: 10.1212/CPJ.0000000000000112
11. Romanelli RJ, Huang Q, Lacy J, et al. Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010–2016. BMC Neurol. 2020;20(163). https://doi.org/10.1186/s12883-020-01749-6
12. African Americans. National Multiple Sclerosis Society website. Accessed December 20, 2020. https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/African-American-Resources
13. Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006;12(6):775-781. doi: 10.1177/1352458506070923
14. The use of disease-modifying therapies in multiple sclerosis: Principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. National Multiple Sclerosis Society website. Published July 2014. Updated September 2019. https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf
15. Amezcua L, Oksenberg JR, McCauley JL. MS in self-identified Hispanic/Latino individuals living in the US. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317725103. doi: 10.1177/2055217317725103
16. Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler. 2017;23(11):1554-1557. doi: 10.1177/1352458516679894
17. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, et al. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010;20(4):451-457.
18. Minden SL, Hoaglin DC, Hadden L, Frankel D, Robbins T, Perloff J. Access to and utilization of neurologists by people with multiple sclerosis. Neurology. 2008;70(13 Pt 2):1141-1149. doi: 10.1212/01.wnl.0000306411.46934.ef
19. Livingston T, Fay M, Iyer R, Wells W, Pill MW. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs.
J Manag Care Spec Pharm. 2016;22(12):1385-1391. doi: 10.18553/jmcp.2016.22.12.1385
20. Chambers JD, Anderson JE, Wilkinson CL, Pallavi R. Variation in the coverage of disease-modifying multiple sclerosis drugs among US payers. Am J Pharm Benefits. 2017;9(5):155-159. https://doi.org/10.18553/jmcp.2016.22.10.1176
21. Bourdette DN, Hartung DM, Whitham RH. Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients. Neurol Clin Pract. 2016;6(2):177-182. doi:10.1212/CPJ.0000000000000208
22. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681-1683. doi: 10.1001/archneur.62.11.1681